<DOC>
	<DOCNO>NCT02077699</DOCNO>
	<brief_summary>The purpose study evaluate efficacy treatment Lactobacillus casei DG reduction painful symptom patient affect irritable bowel syndrome . After , secondary object evaluate reduction painful symptom relate relevant reduction trypsin tryptase colonic mucosa .</brief_summary>
	<brief_title>Efficacy Evaluation Commercial Preparation Containing Lactobacillus Casei DG Reduction Painful Symptoms Related Irritable Bowel Syndrome ( IBS ) . A Pilot Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>outPatients diagnosis Irritable Bowel syndrome ( IBS ) accord Rome III Diagnostic Criteria Functional Gastrointestinal Disorders Previous colonoscopy ( within 24 month prior enrollment ) negative result write informed consent systemic topical therapy steroid glucocorticoid beclomethasone dipropionate budesonide , ongoing within month prior enrollment therapy antibiotic probiotic , ongoing within month prior enrollment inflammatory bowel diseases coproparaxitological examination positive result bowel disease infectious , actinic , endocrine drugrelated origin immunodeficiency diagnosis malignant cancer within 5 year prior enrollment renal , hepatic , hematologic , cardiovascular , pulmonary , neurological , psychiatric , immunological , gastrointestinal endocrine disorder , find clinically relevant severe disease may interfere treatment ; abuse alcohol , drug medication , psychotropic drug diagnosis dementia disorder cause progressive deterioration capacity discernment mental physical disability reduces ability follow prescribe therapy ; previous participation study pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Lactobacillus casei DG</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
</DOC>